Document is current
Any future updates will be listed below
-
Authors
Clarke, Harrison A.
Ma, Xin https://orcid.org/0009-0009-3347-4257
Shedlock, Cameron J.
Medina, Terrymar
Hawkinson, Tara R. https://orcid.org/0000-0002-8743-5503
Wu, Lei https://orcid.org/0000-0002-1474-8082
Ribas, Roberto A. https://orcid.org/0009-0008-9024-1292
Keohane, Shannon
Ravi, Sakthivel https://orcid.org/0000-0002-5159-6030
Bizon, Jennifer L.
Burke, Sara N.
Abisambra, Jose Francisco https://orcid.org/0000-0001-6341-679X
Merritt, Matthew E. https://orcid.org/0000-0003-4617-9651
Prentice, Boone M.
Vander Kooi, Craig W.
Gentry, Matthew S. https://orcid.org/0000-0001-5253-9049
Chen, Li https://orcid.org/0000-0001-9372-5606
Sun, Ramon C. https://orcid.org/0000-0002-3009-1850
- License Information
-
More Information
Article History
Received: 24 August 2023
Accepted: 23 April 2025
First Online: 12 May 2025
Competing interests
: R.C.S. has research support and received consultancy fees from Maze Therapeutics. R.C.S. is a member of the Medical Advisory Board for Little Warrior Foundation and M.S.G. is a member of the science advisory board for Chelsea’s Hope, Glut1-deficiency syndrome, and the adult polyglucosan body disease foundation. M.S.G. has research support and research compounds from Maze Therapeutics, Valerion Therapeutics, Ionis Pharmaceuticals. M.S.G. also received consultant fees from Maze Therapeutics. The remaining authors declare no competing interests.
